434TiP ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC).

Subjects

Subjects :

*ANLOTINIB
*BREAST cancer
*TRASTUZUMAB

Details

Language :

English

ISSN :

09237534

Volume :

35

Database :

Academic Search Index

Journal :

Annals of Oncology

Publication Type :

Academic Journal

Accession number :

179691791

Full Text :

https://doi.org/10.1016/j.annonc.2024.08.381